← Human Trials & Peer-Reviewed Studies
Comparison of intramyometrial vasopressin plus rectal misoprostol with intramyometrial vasopressin alone to decrease blood loss during laparoscopic myomectomy: Randomized clinical trial
Plain-language guide to PMID 30056355 (2018): single-blind randomized controlled trial study of Vasopressin in 30 women.
Key Facts
- PMID
- 30056355
- Journal
- European journal of obstetrics, gynecology, and reproductive biology
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Srivastava S et al. (6 authors)
- DOI
- 10.1016/j.ejogrb.2018.07.006
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vasopressin in this randomized controlled trial publication.
Who Took Part
According to the abstract, 30 women were involved.
By PubMed's age tags, the people studied were teenagers, young adults and adults.
Sixty women with symptomatic leiomyoma scheduled for laparoscopic myomectomy were recruited for the study.
Thirty women received intramyometrial vasopressin plus rectal misoprostol (30 min before procedure) (Group I) and 30 women received intramyometrial vasopressin alone (Group II) during laparoscopic myomectomy.
How the Study Was Run
The researchers set it up as a randomized and single-blind study.
Because people in this Vasopressin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
In this single-blind Vasopressin study one party knew the assignments and the other did not.
A randomized, single-blind, controlled trial was conducted at All India Institute of Medical Sciences, New Delhi, India.
The primary outcome measure was intra-operative blood loss during surgery.
What Was Measured
Topics PubMed links to this paper include Administration, Rectal, Blood Loss, Surgical, Hemostatics, Laparoscopy, Misoprostol, Oxytocics and Uterine Myomectomy.
Author keywords: Vasopressin.
What This Means in Plain Language
The paper is a randomized and single-blind study of Vasopressin in 30 women.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2018 (European journal of obstetrics, gynecology, and reproductive biology), a journal based in Ireland.
More context: the Vasopressin compound page, all human trials.
Our Notes on the Compound
Vasopressin: A 9-amino-acid hormone (antidiuretic hormone) that controls water balance and blood vessel tone; used in septic shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.